glp-1 news today october 9 2025 In the phase 3 ACHIEVE-1 trial, published in June 2025, the oral small-molecule receptor agonist orforglipron significantly reduced the glycated hemoglobin level over a period of 40 weeks in adults with Rising use of GLP-1 medications

Better sleep, faster recovery, and an overall rejuvenated you

Group mean body weight from birth to postpartum day 14 trended lower in F2 generation rats descended from liraglutide-treated rats compared to F2 generation rats descended from controls, but differences did not reach statistical significance for any group

Really understanding how you can deliver something thats very precise to activate a desired target is kind of the beauty and the opportunity of working with peptides, and its interesting, because the opportunities are endless, right? Dr

BMI 27 with obesity-related comorbidities or significant weight loss resistance

Effects of N-acetylcysteine, oral glutathione (GSH), and a novel sublingual form of GSH on oxidative stress markers: a comparative crossover study